Collectively, these findings signify the multifaceted impact of GLP-1 agonists on gut microbiota composition and metabolic health, offering promising ways for the development of targeted therapeutic interventions for obesity and related metabolic disorders. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.